Open AccessControversial Use of Antibiotics in Patient with Sars-Cov-2
Author(s) -
Carlos Mauricio Vergara Lobo
Publication year - 2021
Publication title -
international journal of pharmaceutical and bio-medical science
Language(s) - English
Resource type - Journals
eISSN - 2767-830X
pISSN - 2767-827X
DOI - 10.47191/ijpbms/v1-i6-02
Subject(s) - pneumonia , viral pneumonia , coronavirus , medicine , superinfection , covid-19 , virology , ards , antibiotics , intensive care medicine , common cold , outbreak , disease , virus , immunology , biology , infectious disease (medical specialty) , microbiology and biotechnology , lung
Background: The SARS-CoV-2 coronavirus is a new type of coronavirus that can affect people and the disease it causes is called COVID-19. Coronaviruses are enveloped RNA viruses that cause respiratory illnesses of varying severity, from the common cold to deadly pneumonia. The WHO first learned of the existence of this new virus on December 31, 2019, when it was informed of a group of cases of "viral pneumonia" that had been declared in Wuhan. Methodology: A narrative review was carried out through various databases from January 2020 to June 2021; the search and selection of articles was carried out in journals indexed in English. The following keywords were used: Coronavirus, Sars-Cov 2, Covid 19, ARDS in Covid 19, Antibiotics Associated with Sars-Cov 2 Results: There are no controlled clinical trials evaluating the use of empirical antimicrobials in patients with COVID-19 or other coronaviruses. Therefore, the recommendations are based on extrapolation of data from other viral pneumonias that may suffer from bacterial superinfection, particularly viral pneumonias due to influenza. Conclusions: The present review seeks to clarify the functional role that antimicrobials have with respect to infection by sars-cov 2 (COVID-19), in which circumstances they are necessary to use them and which do not merit it.